Display options
Cite
Zimering MB. Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway. J Endocrinol Diabetes. 2017;4(4)doi: 10.15226/2374-6890/4/4/00184.
Zimering, M. B. (2017). Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway. Journal of endocrinology and diabetes, 4(4), . https://doi.org/10.15226/2374-6890/4/4/00184
Zimering, Mark B. "Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway." Journal of endocrinology and diabetes vol. 4,4 (2017). doi: https://doi.org/10.15226/2374-6890/4/4/00184
Zimering MB. Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway. J Endocrinol Diabetes. 2017;4(4). doi: 10.15226/2374-6890/4/4/00184. Epub 2017 Oct 04. PMID: 29805993; PMCID: PMC5964990.
Copy Download .nbib Format: NLM
Share it on

J Endocrinol Diabetes. 2017;4(4). doi: 10.15226/2374-6890/4/4/00184. Epub 2017 Oct 04.

Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway.

Journal of endocrinology and diabetes

Mark B Zimering

Affiliations

  1. Endocrinology, Veterans Affairs New Jersey Healthcare System, East Orange, New Jersey; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey.

PMID: 29805993 PMCID: PMC5964990 DOI: 10.15226/2374-6890/4/4/00184

Abstract

AIMS: To identify the G-protein coupled receptor(s) on neuroblastoma and endothelial cells which mediate neural- and endothelial cell-inhibitory effects in plasma autoantibodies from a subset of older type 2 diabetes with neurologic and vascular co-morbidity. To determine the mechanism(s) of neurite retraction induced by diabetic pathologies' auto antibodies.

METHODS: Protein-A eluates from plasma of 11 diabetic patients having nephropathy, moderate-severe obesity and/or complications in which increased inflammation plays a role (depression, Parkinson's disease, atrial fibrillation, obstructive sleep apnea) were tested for neurite retraction and decreased survival in N2A neuroblastoma cells, and decreased survival in pulmonary artery endothelial cells. Specific antagonists of G protein coupled receptors belonging to the G alpha q subfamily of hetero trimetric G proteins or the phospholipase C/inositol triphosphate/Ca2+ pathway were tested for modulatory effects on diabetic pathologies' autoantibody-induced N2A neurite retraction, or cell survival.

RESULTS: Co-incubation with specific antagonists of the 5-hydroxytryptamine- 2A receptor significantly prevented acute N2A neurite retraction induced by 50-100 nM concentrations of diabetic pathologies' autoantibodies. Protection against neurite retraction (M100907> spiperone> ketanserin) closely paralleled the antagonists' potency order at the 5-HT2-AR. Neuroblastoma or endothelial cell death (after 24 hours incubation) with 50-100 nM autoantibodies was completely or nearly completely (91%) prevented by co-incubation with 200 nM M100907, a highly selective 5-HT2-AR antagonist. Alpha-1 adrenergic, angiotensin II, metabotropic glutamate 5, or endothelin A (100 nM-10µM) receptor antagonists did not substantially inhibit autoantibody-induced cell death. The intracellular calcium chelator (BAPTA-AM, 50 µM) and inhibitors of the inositol triphosphate (IP3) receptor (2-APB, 50µM), and phospholipase C-gamma (U73144, 1µM) each significantly protected against autoantibody-induced acute N2A neurite retraction.

CONCLUSION: These data suggest that neural- and endothelial- inhibitory effects in autoantibodies from older adult diabetes with nephropathy and obesity/inflammation-associated complications are mediated by agonist autoantibodies directed against the 5-hydroxytryptamine 2 receptor positively coupled to the phospholipase C/inositol triphosphate/ cytosolic Ca2+ release pathway.

Keywords: 5-hydroxytryptamine-2 receptor; autoantibodies; diabetes; neurovascular diseases

References

  1. Diabetologia. 1989 Apr;32(4):219-26 - PubMed
  2. Brain Res Bull. 2000 Apr;51(6):499-505 - PubMed
  3. J Biol Chem. 2003 Jul 18;278(29):26788-92 - PubMed
  4. J Cell Physiol. 1989 Jun;139(3):570-9 - PubMed
  5. J Neurochem. 1999 May;72(5):2206-14 - PubMed
  6. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:64-72 - PubMed
  7. Prog Clin Biol Res. 1989;317:333-51 - PubMed
  8. Adv Cardiol. 2011;46:43-66 - PubMed
  9. Brain Res. 2009 Jan 28;1251:276-86 - PubMed
  10. Hippocampus. 2006;16(3):239-49 - PubMed
  11. Crit Rev Biochem Mol Biol. 2010 Dec;45(6):555-66 - PubMed
  12. Br J Pharmacol. 1996 Mar;117(6):1081-8 - PubMed
  13. Life Sci. 2002 Nov 8;71(25):2939-59 - PubMed
  14. J Biol Chem. 2017 Apr 14;292(15):6352-6368 - PubMed
  15. J Pharmacol Exp Ther. 1996 May;277(2):968-81 - PubMed
  16. Am J Physiol. 1999 Jun;276(6 Pt 2):F922-30 - PubMed
  17. Front Endocrinol (Lausanne). 2013 Nov 22;4:183 - PubMed
  18. J Biol Chem. 2005 Mar 4;280(9):8041-50 - PubMed
  19. J Biol Chem. 2011 Jun 17;286(24):21118-28 - PubMed
  20. Br J Pharmacol. 1995 Jun;115(4):622-8 - PubMed
  21. Proc Natl Acad Sci U S A. 2001 Feb 13;98 (4):1601-6 - PubMed
  22. Mol Pharmacol. 1996 Aug;50(2):306-13 - PubMed
  23. N Engl J Med. 2013 Nov 14;369(20):1892-903 - PubMed
  24. Diabetes. 2002 Apr;51(4):1157-65 - PubMed
  25. Front Mol Neurosci. 2010 Jul 30;3:null - PubMed
  26. J Clin Endocrinol Metab. 2009 Jun;94(6):2171-7 - PubMed
  27. J Endocrinol Diabetes. 2017;4(1):null - PubMed
  28. Diabetes Res Clin Pract. 2011 Jul;93(1):95-105 - PubMed
  29. Front Endocrinol (Lausanne). 2014 Aug 11;5:128 - PubMed
  30. J Endocrinol Diabetes. 2016;3(1):null - PubMed
  31. Front Endocrinol (Lausanne). 2013 May 15;4:58 - PubMed

Publication Types